AMAP1 is an oncogene in various cancers, and high AMAP1 levels predict inferior outcomes in patients with triple-negative breast cancer (He et al., 2020), ovarian cancer (Hou et al., 2014), colorectal cancer (Muller et al., 2010), and laryngeal squamous cell carcinoma (Li et al., 2014). This evidence concerns the gene ASAP1 and laryngeal squamous cell carcinoma.